Introduction
============

The survival rate for pancreatic ductal adenocarcinoma (PDAC) is among the worst for any cancer due to the lack of effective means for screening and early diagnosis [@B1], [@B2]. Gemcitabine is the first line chemotherapy given to patients with advanced or unresectable PDAC [@B3], [@B4] but response varies greatly. Accumulating evidence indicates that genetic factors may play important roles in tumorigenesis and response to chemotherapy [@B5]-[@B7]. In recent years, efforts have been made to identify susceptibility loci associated with sporadic PDAC through genome-wide association studies (GWAS) [@B8]-[@B13], which have provided further understanding of the pathogenesis of the disease. However, clinical utilization of the GWAS findings as specific biomarkers for early detection and diagnosis remains limited, and one of the major obstructions is lack of a functional mechanism [@B14]. Thus, functional characterization of GWAS-identified genetic variants has a fundamental merit.

The strongest association signal in our previous GWAS of PDAC was rs372883T\>C variation located in the 3\'-untranslated region (3\'UTR) of the BTB and CNC homology 1 gene (*BACH1*) on 21q21.3. The C allele was associated with significantly decreased PDAC risk compared with the T allele [@B11]. Nevertheless, the role of *BACH1* variant in the development of PDAC remains unclear. *BACH1*, ubiquitously expressed in various tissues [@B15]-[@B17], is a transcriptional repressor of *HMOX1* encoding heme oxygenease-1 (HO-1), a rate-limiting enzyme in heme catabolism. At low heme level, *BACH1* binds directly to the *HMOX1* enhancer and represses HO-1 expression; however, at high heme concentration, the bound *BACH1* is relieved, resulting in the upregulation of HO-1 [@B18]. HO-1 may also play important roles in other cellular processes such as oxidative stress, metabolic inflammation, cell cycle, apoptosis and angiogenesis [@B19]-[@B23]. Thus, disruption of feedback regulation in the BACH1/HO-1 pathway may be implicated not only in cancer development but also in the sensitivity of cancer cells to chemotherapeutic agents.

Since rs372883C\>T variation located in the *BACH1* 3\'UTR might disrupt the binding of certain regulatory microRNAs and thus affect *BACH1* expression, in this study, we performed functional analysis of rs372883 variants and examined the effects of altered BACH1/HO-1 signaling pathway on the phenotypes of PDAC cells. In addition, we investigated whether *BACH1* rs372883 variation is associated with response to gemcitabine chemotherapy and survival time in PDAC patients.

Methods
=======

Study subjects
--------------

Subjects with PDAC (N=102) were recruited between November 2002 and December 2014 (**Table [S1](#SM0){ref-type="supplementary-material"}**). Among them, 82 were treated with gemcitabine alone while the other 20 were treated with gemcitabine after surgical resection at a dose of 1,000 mg/m^2^ delivered on days 1, 8 and 15 every 28 days. Responsiveness was evaluated with RECIST criteria [@B24] after accomplishing at least two courses of treatment. We defined patients achieving complete response (CR) or partial response (PR) as responders, and patients with stable disease (SD) or progressive disease (PD) as nonresponders. Survival time was measured from the date of diagnosis to the date of last follow-up or death. The last date of follow-up was 30th May 2015 and the median follow-up time was 33 months. Patients alive on the last follow-up date were considered censored. Twelve patients were lost to follow-up during this period and therefore only 90 patients were included in the survival analysis. Informed consent was obtained from all participants, and this study was approved by the Institutional Review Board of the Chinese Academy of Medical Sciences Cancer Hospital. All experiments on the participants in this study were performed in accordance with the relevant guidelines and regulations.

Analysis of *BACH1* genotypes
-----------------------------

A blood DNA sample was obtained from each subject at the time of diagnosis and the *BACH1* rs372883 genotypes were determined using a TaqMan genotyping platform (ABI 7900HT system) with the primers and probes shown in **Table [S2](#SM0){ref-type="supplementary-material"}**.

In silico analysis of interaction between *BACH1* 3\'UTR and microRNAs
----------------------------------------------------------------------

We used publicly available software FINDTAR3 (<http://bio.sz.tsinghua.edu.cn/>), RegRNA (<http://regrna.mbc.nctu.edu.tw/php/prediction.php>) and SnipMir (<http://www.microarray.fr:8080/merge/index?action=MISNP>) to analyze the potential interactions between different *BACH1* 3\'UTR sequences and microRNAs.

Cell lines and cell culture
---------------------------

Human PDAC cell lines CFPAC-1, BXPC-3 and Capan-2, human umbilical vein endothelial cell line HUVEC and human embryonic kidney cell line 293T were purchased from the China Infrastructure of Cell Line Resources (Beijing). Cells passaged for less than 6 months were authenticated by DNA fingerprinting analysis using short-tandem repeat (STR) markers.

Reporter gene construction and luciferase reporter assays
---------------------------------------------------------

The full length of *BACH1* 3\'UTR amplified from a rs372883TT homozygous DNA sample was subcloned into the psiCHECK-2 vector (Promega) and designated as p-T~rs372883~, which was site-specifically mutated to create its variant counterparts p-C~rs372883~. The constructs were transfected respectively into CFPAC-1 and BXPC-3 cells with or without miR-1257. Renilla luciferase activity was detected with a Dual-Luciferase Reporter Assay System (Promega) and normalized using the firefly luciferase activity.

RNA preparation and quantitative real-time PCR (qRT-PCR) analysis
-----------------------------------------------------------------

Total RNA was extracted from PDAC cell lines and surgically removed pancreatic specimens from 75 individuals. First-strand cDNA was synthesized by using the Superscript II-reverse transcriptase kit (Invitrogen). qRT-PCR was accomplished using the SYBR Green method on an ABI Prism 7900HT system.

Northern blot of microRNA
-------------------------

Total RNA extracted from CFPAC-1 and BXPC-3 cells was separated on denaturing polyacrylamide gels and transferred to Immobilon-Ny^+^ Membrane (Millipore, INYC00010). After pre-hybridization in DIG Easy Hyb buffer (Roche, 12039672910), the membrane was hybridized with the denatured 3\'-digoxigenin-labeled complementary sequence of miR-1257 probe (**Table [S2](#SM0){ref-type="supplementary-material"}**) and detected using an Odyssey infrared scanner (Li-Cor, Lincoln).

Plasmids, lentiviral production and transduction
------------------------------------------------

*BACH1* cDNA made from CFPAC-1 cells was PCR-amplified and subcloned into pLvx-IRES-Neo vector (Clontech). Two short hairpin RNAs (shRNAs) were synthesized (GenePharma) for *BACH1* suppression (**Table [S2](#SM0){ref-type="supplementary-material"}**). They were respectively inserted into the pSIH1-H1-Puro lentiviral shRNA vector (System Biosciences) to produce lentivirus in 293T cells. CFPAC-1 and BXPC-3 cells were infected with concentrated virus. The supernatant was replaced with complete culture media after 24 h, followed by selection with G418 or puromycin, respectively.

Gene expression profiling, gene ontology and gene set enrichment analysis
-------------------------------------------------------------------------

Total RNA extracted from CFPAC-1 cells with or without *BACH1* knockdown were subject to analysis by the Agilent human lncRNA+mRNA array V.4.0 platform (Agilent Technologies). The raw and processed microarray data have been submitted to the Gene Expression Omnibus (accession number GSE111506). For Gene Ontology (GO) analysis, differentially expressed protein-coding genes were uploaded to online software DAVID (<http://david.abcc.ncifcrf.gov/>) and *P*\<0.05 was considered significant for the biological process enrichment. For Gene Set Enrichment Analysis (GSEA), gene profiling data were uploaded to GSEA 3.0. Hallmark gene sets were obtained from MSigDBv6.1 (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>). False discovery rate (FDR) \<0.25 was considered significant for enriched biological pathways.

Transient overexpression and RNA interference of *HMOX1*
--------------------------------------------------------

Full length of *HMOX1* cDNA was PCR-amplified from total RNA isolated from CFPAC-1 cells and the fragment was subcloned into the pcDNA3.1 vector (Invitrogen). Small interfering RNA (siRNA) targeting *HMOX1* and its scramble control (**Table [S2](#SM0){ref-type="supplementary-material"}**) were obtained from GenePharma. Transfections were done with lipofectamine 2000.

Western blot assays
-------------------

Total protein (60 μg) extracted from cells or tissue samples was resolved by SDS-PAGE and transferred to PVDF membrane (Millipore). Antibody against BACH1 (A303-057A) was from Bethyl Laboratories while antibodies against other proteins were from Abcam (HO-1, ab52947; ERK1/2, ab36991; phosphorylated ERK1/2, ab76299; NRF2, ab62352; OCT4, ab181557; ABCG2, ab207732; ALDH1, ab52492 and TRA-1-60, ab16288), Santa-Cruz (HIF1A, sc-10790; VEGF, sc-152 and β-ACTIN, sc-47778) and Cell Signaling Technology (AKT, \#9272; phospho-AKTThr308, \#9275; phospho-AKTSer473, \#9271; PTEN, \#9559; eNOS, \#9586; phospho-eNOSSer1177, \#9570; E-CADHERIN, \#3195; VIMENTIN, \#5741; ZO-1, \#8193; ZEB1, \#3396 and SLUG, \#9585). The membranes were incubated with the primary antibody and visualized with a Phototope-horseradish peroxidase Western Blot Detection kit (Cell Signaling Technology).

Chromatin immunoprecipitation combined quantitative PCR (ChIP-qPCR)
-------------------------------------------------------------------

CFPAC-1 and BXPC-3 cells were treated with formaldehyde for cross linking, followed by ChIP with antibody against BACH1 (Santa-Cruz, sc-14700X), NRF2 (Abcam, ab62352) or mouse IgG. The level of *HMOX1* was determined by qPCR using SYBR Green and the primers for *HMOX1* and its enhancer regions 1 and 2 [@B25], [@B26].

Cell viability and colony formation assays
------------------------------------------

Cell viability was measured using CCK-8 kit (Dojindo). Colony formation ability was determined by counting number of cells in 12-well cell-culture cluster with complete growth media after fixing with methanol and stained with crystal violet.

Enzyme-linked Immunosorbent assay (ELISA) of VEGF protein
---------------------------------------------------------

CFPAC-1 and BXPC-3 cells with overexpression or knockdown of *BACH1* were cultured in a complete medium for 48h. The culture medium was collected for ELISA of VEGF using the VEGF ELISA kit (R&D System).

*In vitro* angiogenesis assays
------------------------------

HUVECs were seeded at a density of 2×10^4^ cells per well on growth factor-reduced Matrigel (Corning 356231) and grown in a conditioned medium collected from CFPAC-1 or BXPC-3 cells with overexpression or knockdown of *BACH1*. The morphologic change of HUVECs was photographed and tube formation was counted after cultivation for 6h.

Drug sensitivity assays
-----------------------

Cells in growth medium were exposed to various concentrations of gemcitabine (Selleck, S1714) and enumerated using CCK-8 kit at 48 h of exposure. Gemcitabine sensitivity was expressed as drug concentration that inhibits cell proliferation by 50% (IC~50~).

Xenograft tumor formation assays
--------------------------------

Five-week old female BALB/c nude mice (6 animals in each group) were subcutaneously injected with 0.1 mL of cell suspension containing 1×10^6^ cells into the back flank. Animals were raised in the following six weeks and tumor volume was measured every other day and calculated by length×width^2^ ×0.5. Sample size was not predetermined for these experiments. All experimenters were blinded to which cells were injected in the mice. All animal handling and experimental procedures were performed in accordance with the relevant institutional and national guidelines.

Immunohistochemical (IHC) analysis
----------------------------------

Tissue microarrays of PDAC and paired normal tissues (N=67) were incubated with the mouse anti-BACH1 antibody (1:100; Abcam, ab128486) and detected with the ABC kit (Pierce). The BACH1 labeling index was ranked according to the percentage of positive cell nuclei and staining scores were calculated using an immunoreactive scoring (IRS). BACH1 labeling score of intensity was estimated as negative (0), weak (1), moderate (2) and strong (3). The extent of staining, defined as the percentage of positive staining cells, was scored as 1 (≤10%), 2 (11%-50%), 3 (51%-75%) and 4 (\>75%). The total IRS was obtained by multiplying the score of intensity and that of extent, ranking from negative to \>6 (+++). Owing to limited sample size, IRS was categorized into weak expression group (IRS\<4) and strong expression group (IRS≥4).

Statistical analysis
--------------------

The statistical significance of comparison between two groups was determined using Student\'s *t*-test. Wilcoxon matched-pairs test was used to assess IHC IRS score within cancer and matched normal tissues. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated using logistic regression model adjusting for sex, age, tumor stage and surgery. Hazard rations (HRs) and their 95% CIs were calculated using Cox proportional hazard models and adjusted for covariates that might influence the length of survival, including sex, age, tumor stage and surgery. Kaplan-Meier survival estimates were plotted, and the significances were assessed using log-rank tests. All statistical analyses were performed using SPSS (version 20.0, SPSS Inc.). *P*\<0.05 was considered statistically significant.

Results
=======

*BACH1* is downregulated in PDAC
--------------------------------

We first examined the expression status of *BACH1* in PDAC and normal tissues and found that 76.0% (57/75) of tumors expressed significantly lower *BACH1* mRNA than their adjacent normal tissues (*P*\<0.0001; **Figure [1](#F1){ref-type="fig"}A**). Western blot analysis of randomly selected 35 pairs of samples showed that 23 (65.7%) had lower *BACH1* protein levels in tumors than in normal tissues (**Figure [1](#F1){ref-type="fig"}B**). IHC staining of *BACH1* on tissue microarrays revealed strong signals in both cytoplasm and nuclei of normal pancreatic duct cells and acinar cells; however, *BACH1* staining was apparently reduced in tumors (**Figure [1](#F1){ref-type="fig"}C**). Two published data sets [@B27], [@B28] also showed significantly lower *BACH1* mRNA in PDAC than in normal tissues (**Figures [1](#F1){ref-type="fig"}D-E**), consistent with our results.

*BACH1* inhibits in vitro PDAC cell proliferation and angiogenesis
------------------------------------------------------------------

To explore the whole landscape of gene expression programs regulated by *BACH1* in PDAC, we performed gene expression profile analysis in CFPAC-1 cells with or without *BACH1* knockdown. Gene ontology analysis showed that differentially expressed genes were enriched in many pathways including transcription, redox process, RAS signal transduction, cell proliferation, stem cell maintenance, cell migration, vascular endothelial growth factor receptor signaling pathway, apoptotic process and positive regulation of epithelial to mesenchymal transition (**Figure [S1](#SM0){ref-type="supplementary-material"}A**). Gene set enrichment analysis revealed that genes upregulated in CFPAC-1 cells with *BACH1* knockdown were enriched in ROS pathway, glycolysis, angiogenesis, complement, xenobiotic metabolism, MTORC1 signaling, hypoxia, MYC targets, P53 pathway and epithelial-mesenchymal transition (**Figure [S1](#SM0){ref-type="supplementary-material"}B** and**Table [S3](#SM0){ref-type="supplementary-material"}**). Based on these findings, we next examined the impact of *BACH1* on PDAC cell proliferation by altering *BACH1* expression in CFPAC-1 and BXPC-3 cells (**Figure [2](#F2){ref-type="fig"}A**). Overexpression of *BACH1* substantially inhibited colony formation (**Figure [2](#F2){ref-type="fig"}B**) and cell proliferation (**Figure [2](#F2){ref-type="fig"}C**) while knockdown of *BACH1*expression accelerated colony formation and proliferation abilities of cells (**Figures [2](#F2){ref-type="fig"}B** and **2D**). The inhibitory effect of *BACH1* on PDAC cell proliferation was also replicated in vivo by xenograft growth in mice (**Figures [2](#F2){ref-type="fig"}E-F**). To explore the effect of *BACH1* on angiogenesis, we first examined the VEGF levels secreted by CFPAC-1 and BXPC-3 cells in the culture medium and the results showed that overexpression of *BACH1* significantly suppressed VEGF levels in the supernatant but knockdown of *BACH1*expression significantly elevated the levels (**Figure [2](#F2){ref-type="fig"}G**). In vitro angiogenesis assays using HUVEC model showed that tube formation was greatly enhanced by culture with the supernatants from PDAC cells having *BACH1* knockdown compared with that by culture with the supernatants from cells having *BACH1* overexpression (**Figure [2](#F2){ref-type="fig"}H**).

*BACH1* negatively regulates HO-1 expression
--------------------------------------------

To shed light on the underlying molecular mechanism that *BACH1* may act, we combined published *BACH1* ChIP-sequencing data (GEO accession: GSM693953 and GSM693952) [@B29] and differentially expressed genes (fold change\>1.5 or \<-1.5) identified by our microarray analysis. We found 8 genes that were directly regulated by *BACH1* and, among them, *HMOX1* was the mostly upregulated one (**Figure [3](#F3){ref-type="fig"}A** and**Figure [S2](#SM0){ref-type="supplementary-material"}**). We confirmed that *BACH1* can bind to the *HMOX1* enhancers [@B29] (**Figures [3](#F3){ref-type="fig"}B-C**) and overexpression of *BACH1* substantially suppressed HO-1 expression while knockdown of *BACH1* substantially increased HO-1 expression in PDAC cell lines (**Figure [3](#F3){ref-type="fig"}D**). Furthermore, we found that *HMOX1* levels were significantly higher in PDAC than in normal pancreatic tissues (*P*\<0.0001; **Figure [3](#F3){ref-type="fig"}E**) and were negatively correlated with *BACH1* levels (**Figures [3](#F3){ref-type="fig"}F-H**). *NRF2* is thought to be a transactivator in NRF2/BACH1 transcriptional network. However, we found that the change of *BACH1* expression had no effect on *NRF2* expression at both mRNA and protein levels (**Figure [S3](#SM0){ref-type="supplementary-material"}A**). ChIP-qPCR assays showed that *NRF2* can also bind to the *HMOX1* enhancers. However, when *BACH1* was overexpressed in cells, less *NRF2* was enriched in EN1 and EN2; in contrast, when *BACH1* expression was knocked down, more *NRF2* was enriched in EN1 and EN2 (**Figure [S3](#SM0){ref-type="supplementary-material"}B**).

*BACH1* controls cell proliferation and angiogenesis via regulating HO-1 expression
-----------------------------------------------------------------------------------

We further examined the impact of HO-1 on PDAC cell proliferation under the *BACH1* overexpression or knockdown condition. When *BACH1* was overexpressed in CFPAC-1 and BXPC-3 cells, HO-1 was substantially reduced; however, forced restoration of HO-1 expression in cells efficiently overcame the repression of cell proliferation and colony formation caused by overexpression of *BACH1* (**Figures S4A-B**). In contrast, silencing HO-1 expression successfully suppressed proliferation and colony formation caused by knockdown of *BACH1* expression in the same cells (**Figures S4C-D**). These results suggest that the effect of *BACH1* on cell proliferation is largely mediated by HO-1. We then examined the changes of molecules downstream HO-1 focusing on aberrant activation and regulation of AKT, ERK, eNOS, HIF1A, PTEN and VEGF, which has been well-known to be involved in cancer cell proliferation and angiogenesis [@B30]-[@B33]. We found that when *BACH1* was overexpressed in CFPAC-1 and BXPC-3 cells, HO-1 and phosphorylated AKT, eNOS and ERK1/2 were substantially reduced, although the total amount of AKT, eNOS and ERK1/2 were not significantly changed (**Figure [4](#F4){ref-type="fig"}A**). In addition, we also observed substantially decreased expression of *HIF1A* and *VEGF* and increased expression of *PTEN* in cells overexpressing *BACH1* (**Figure [4](#F4){ref-type="fig"}A** and **Figure [S5](#SM0){ref-type="supplementary-material"}**). These changes caused by alterations of *BACH1* expression could be rescued when HO-1 expression was restored (**Figures [4](#F4){ref-type="fig"}A-B**). In line with these results in vitro in cells, we detected a reverse correlation between *BACH1* and *HIF1A* (**Figure [4](#F4){ref-type="fig"}C**) or *VEGF* (**Figure [4](#F4){ref-type="fig"}D**) mRNA expression and a positive correlation between *BACH1* and *PTEN* mRNA expression (**Figure [4](#F4){ref-type="fig"}E**) in both clinical PDAC and normal pancreatic tissues.

*BACH1* 3\'UTR*-*rs372883T variant is a target of miR-1257
----------------------------------------------------------

To elucidate the effect of the rs372883T\>C change on *BACH1* expression, we carried out reporter gene assays in CFPAC-1 and BXPC-3 cells. The results showed that the plasmid constructs containing the *BACH1* 3\'UTR-rs372883T had significantly decreased luciferase expression compared with the *BACH1* 3\'UTR*-*rs372883C counterparts (**Figure [5](#F5){ref-type="fig"}A**), suggesting that the rs372883T\>C change may be a functional variation. In silico analysis showed that rs372883 lies within a binding site for the seed region of miR-1257 (MI0006391), the microRNA first described by Morin et al [@B34] and confirmed by Northern blot analysis in the present study (**Figure [S6](#SM0){ref-type="supplementary-material"}**). rs372883T\>C change causes a base pair mismatch between miR-1257 and the *BACH1* 3\'UTR (**Figure [5](#F5){ref-type="fig"}B**). The expression of reporter vectors p-T~rs372883~ and p-C~rs372883~ were then compared in PDAC cells in the presence of exogenous miR-1257 and the results showed that although miR-1257 had no effect on the expression of vector containing the *BACH1* 3\'UTR-rs372883C (p-C~rs372883~), it significantly suppressed the expression of vector containing the *BACH1* 3\'UTR-rs372883T (p-T~rs372883~). The suppressive effect of miR-1257 was in a dose-dependent manner and could be restored by co-transfection of the miR-1257 inhibitor (**Figure [5](#F5){ref-type="fig"}C**).

We then evaluated the association between rs372883 genotypes and *BACH1* mRNA levels in clinical normal pancreatic tissues (N=75) and found that the *BACH1* mRNA levels were significantly lower in the rs372883 TT or CT genotype than that in the CC genotype (**Figure [5](#F5){ref-type="fig"}D**). However, these genotype-associated differences were not related to the miR-1257 levels because no significant differences in miR-1257 expression were observed among individuals (**Figure [5](#F5){ref-type="fig"}E**). As expected, *HMOX1* mRNA levels were significantly higher in the *BACH1* rs372883TT or CT genotype compared with that in the CC genotype (**Figure [5](#F5){ref-type="fig"}F**). These results suggest that rs372883T\>C change may diminish the interaction between *BACH1* 3\'UTR and miR-1257, enhancing *BACH1* expression which further negatively regulates HO-1 expression in a *BACH1* variant-dependent manner. Western blot analysis showed that PDAC specimens with the rs372883TT genotype had substantially lower *BACH1* protein levels but substantially elevated levels of activated signaling molecules that are critical in cell proliferation and angiogenesis such as phosphorylated-AKT, -ERK, -eNOS, *HIF1A* and *VEGF* compared with those with the rs372883CC genotype except for *PTEN*, which was substantially lower in the TT or CT genotype compared with the CC genotype (**Figure [5](#F5){ref-type="fig"}G**).

Sensitivity to gemcitabine in PDAC cells depends on *BACH1* in an allele-specific manner
----------------------------------------------------------------------------------------

Since response to gemcitabine varies greatly among patients, we performed drug sensitivity assays in PDAC cells by altering *BACH1* expression. We found that compared with vector controls, overexpression of *BACH1* significantly increased the sensitivity of both CFPAC-1 and BXPC-3 cells to gemcitabine but knockdown of *BACH1* substantially decreased the sensitivity (**Figure [6](#F6){ref-type="fig"}A**). Because *BACH1* is a suppressor for HO-1 expression, we thus investigated whether *BACH1*-dependent gemcitabine sensitivity is mediated by HO-1. We found that restoration of HO-1 expression in both CFPAC-1 and BXPC-3 cells overexpressing *BACH1* partially suppressed the sensitivity (**Figure [6](#F6){ref-type="fig"}B**), but silencing HO-1 expression in cells with knockdown of *BACH1* partially increased the sensitivity (**Figure [6](#F6){ref-type="fig"}C**).

We then looked at the effects of different rs372883 genotypes on gemcitabine sensitivity and found that in the absence of miR-1257, BXPC-3 cells carrying the rs372883CC genotype had an IC~50~ that is significantly lower than CFPAC-1 cells carrying the rs372883CT genotype and Capan-2 cells carrying the rs372883TT genotype (**Figures [6](#F6){ref-type="fig"}D-F**). The presence of miR-1257 in the assay system significantly increased IC~50~ for Capan-2 (*P*=0.0390) and CFPAC-1 (*P*=0.0006) but not for BXPC-3 (*P*\>0.05) cells, with the fold-change being 7.32, 4.06 and 1.92, respectively (**Figures [6](#F6){ref-type="fig"}D-F** and **Figure [S7](#SM0){ref-type="supplementary-material"}**), indicating a *BACH1* allele-dependent effect of miR-1257. Furthermore, the effect of miR-1257 on gemcitabine resistance in PDAC cells could be restored by co-transfection with the miR-1257 inhibitor (**Figures [6](#F6){ref-type="fig"}D-F**).

To further elucidate the mechanism for the gemcitabine sensitivity dependent on *BACH1* allele, we examined expressions of some drug-resistant genes including *ABCC2*, *MGST1* and *NQO1* in PDAC cells and found that in the presence of miR-1257, the expression of *ABCC2* (*P*=0.0005 and *P*=0.0019), *MGST1* (*P*=0.0002 and *P*\<0.0001) and *NQO1* (*P*=0.0002 and *P*=0.0048) significantly increased in Capan-2 and CFPAC-1 cells but not in BXPC-3 cells (all *P*\>0.05; **Figures S8A-C**). Furthermore, the effect of miR-1257 on the expression of these drug-resistant genes in PDAC cells could be restored by co-transfection with the miR-1257 inhibitor (**Figure [S8](#SM0){ref-type="supplementary-material"}A-C**).

*BACH1* regulates expression of genes involved in EMT and stemness
------------------------------------------------------------------

GO and GSEA results suggested that *BACH1* may be involved in regulating EMT and cell pluripotency processes (**Figures S1A-B** and**Table [S3](#SM0){ref-type="supplementary-material"}**). We then examined the alteration of EMT associated markers in cells with *BACH1* overexpression or downregulation and found that when *BACH1* was overexpressed in CFPAC-1 and BXPC-3 cells, the levels of *E-cadherin* and *ZO-1* were substantially increased but mesenchymal markers *ZEB1*, *Vimentin* and *Slug* were substantially reduced. The reverse results were observed in the same cells with *BACH1* knockdown (**Figure [S9](#SM0){ref-type="supplementary-material"}A**). In addition, we found that stemness markers *ABCG2* and *ALDH1* were substantially reduced when *BACH1* was overexpressed, but substantially increased when *BACH1* was knocked down (**Figure [S9](#SM0){ref-type="supplementary-material"}B**). However, we did not observe any changes of *OCT4*; *TRA-1-60* was not detectable in both cell lines (**Figure [S9](#SM0){ref-type="supplementary-material"}B**). By analyzing previously published results, we observed that the expression levels of *BACH1* were negatively correlated with *ABCG2* and *CXCR4* levels (**Figure [S9](#SM0){ref-type="supplementary-material"}C-D**).

*BACH1* genotypes may predict gemcitabine response and prognosis in PDAC patients
---------------------------------------------------------------------------------

In 102 patients treated with gemcitabine, we observed a response rate of 15.7% and this was not related to the select clinical characteristics such as sex, age, tumor stage and surgery. The *BACH1* rs372883 genotypes appeared to have an ability to identify responsiveness: among responders, 37.5% of individuals carried the CC genotype, while among nonresponders, only 11.6% of individuals carried the CC genotype (*P*=0.024). The adjusted odds ratio of the CC genotype for being nonresponders was 0.15 (95% CI, 0.03-0.68) compared with the TT genotype (**Table [1](#T1){ref-type="table"}**). However, there was no significant difference for the heterozygous CT genotype in responders and nonresponders (37.5% versus 46.5%, *P*=0.745). In this set of patients, 85 (83.3%) had died before the last follow-up time and the median survival time (MST) was 9.3 months. We observed significantly different survival times by tumor stage, with the MST being 14.4, 10.0 and 7.8 months for patients with local, locally advanced and metastatic tumor, respectively (*P*~log-rank~=0.006; **Figure [7](#F7){ref-type="fig"}A**). Patients who responded to gemcitabine also had longer MST than those who did not respond to the regimen (12.3 versus 8.2 moths; **Figure [7](#F7){ref-type="fig"}B**) although the difference did not reach statistical significance (*P*~log-rank~=0.175) probably due to limited sample size. We then evaluated the association between *BACH1* rs372883 genotypes and PDAC survival time and found that the MST for the rs372883CC, CT and TT genotypes was 11.3, 9.8 and 7.5 months (*P*~log-rank~=0.039; **Figure [7](#F7){ref-type="fig"}C**). The per-allele hazard ratio for PDAC death was 0.63 (95% CI, 0.44-0.90; *P*=0.01).

Discussion
==========

In the previous GWAS, we identified rs372883 variant in *BACH1* 3\'UTR as a genetic susceptibility locus for the development of PDAC [@B11]. The aim of the present study was to elucidate the functional effect of this 3\'UTR variant on *BACH1* expression and its consequential molecular role in PDAC. We demonstrate that *BACH1* is low-expressed in PDAC and knockdown of *BACH1* in PDAC cells provokes AKT and ERK oncogenic signaling via upregulation of HO-1 and thus promotes cell proliferation and angiogenesis. Importantly, we found that rs372883 variant in*BACH1* 3\'UTR lies on a binding site for miR-1257; the T\>C change might diminish miR-1257 binding, resulting in a higher expression of *BACH1*. These experimental findings are consistent with our GWAS results and indicate that higher expression of *BACH1* rs372883C allele may be the underlying mechanism for reduced risk of PDAC in individuals carrying this variant. The supportive evidence for tumor suppressor role of *BACH1* in PDAC is also seen in TCGA database (<http://www.cbioportal.org/index.do>), showing high frequencies of somatic mutations and copy number loss in the *BACH1* locus. However, we notice that some sets of *BACH1* mRNA profiling data from human PDAC in Oncomine database are not in line with our results, which is probably due to use of unpaired samples in these studies. In addition, in the present study, we have extended the results to the potential clinical implication that *BACH1* genotype may be a useful biomarker for the identification of gemcitabine treatment efficacy and prognosis of PDAC.

*BACH1* is broadly expressed in various human tissues [@B15]-[@B17]; however, little was previously known about its role in the development of PDAC. Because *BACH1* is a transcriptional repressor negatively regulating several genes involved in oxidative stress response, cell cycle progression and apoptosis [@B29], it is reasonable to assume that as a potential tumor suppressor, *BACH1* might act through some of these pathways. Indeed, by gene expression profile analysis using mRNAs from PDAC cells with or without *BACH1* knockdown, we found the significant expression changes in several pathways, including those involved in cell proliferation. Previous study has reported that *BACH1* may inhibit proliferation and angiogenesis of HUVECs through suppressing Wnt/β-catenin signaling pathway [@B35]. Other groups have also shown that *BACH1* regulates proliferation of smooth muscle cells during inflammation and atherogenesis [@B36] and proliferation of murine embryonic fibroblasts in premature cellular senescence of these cells [@B37]. It has been reported that knockdown of *BACH1* represses the growth inhibitory function of *CXCR3-B* in breast cancer cells [@B38]. On the other hand, it has been shown that overexpression of miR-155, which can target *BACH1* mRNA, promotes proliferation of renal cancer cells [@B39]. All these findings indicate that BACH1 may regulate cell proliferation. Since *HMOX1* (HO-1) is the main target of *BACH1* and is important in the induction of tumorigenic signaling pathways [@B23], [@B40]-[@B43], in this study we focused on examination of the effects of altered *BACH1* expression on HO-1 and its downstream signaling modules. We demonstrated that in PDAC cells, *BACH1* indeed negatively regulates HO-1 expression. Knockdown of *BACH1* expression substantially increased production of HO-1 and activation of AKT, ERK and eNOS and elevated *HIF1A* and *VEGF* but decreased *PTEN* expression, which consequentially enhanced cell proliferation ability. In contrast, overexpression of *BACH1* in PDAC cells had reversed effects. Furthermore, the effects of *BACH1* overexpression or knockdown could be rescued when HO-1 was concurrently overexpressed or knocked down in PDAC cells. During this process, we found that *NRF2*, the transactivator of *HMOX1*, may modulate the expression of *HMOX1* by competitive binding to *BACH1*. Taken together, these results indicate that the acting mechanism of *BACH1* in the risk of developing PDAC may at least partially depend on HO-1. In addition, we found that *BACH1* could regulate the expression of genes involved in EMT and stemness, which might also contribute to tumor progression and drug resistance.

It has been well known that some microRNAs may induce mRNA cleavage or suppress translation by binding to the 3\'UTR of target mRNA and therefore function as negative regulators of gene expression [@B44]. In the present study, we show for the first time that *BACH1* expression is regulated by miR-1257 and the rs372883T\>C variation diminishes this regulation. Since *BACH1* may function as a tumor suppressor, one may expect that higher constitutional activity of *BACH1* would confer lower risk of cancer formation, which may explain why individuals with the rs372883C allele have reduced PDAC risk compared with those with the rs372883T allele [@B11]. In line with this notion, we detected higher levels of miR-1257 in PDAC tissues compared with their adjacent normal tissues, implicating an oncogenic role of miR-1257 in PDAC. Since miR-1257 has poorly been investigated in malignancies, our results warrant further studies to examine the regulation and oncogenic role of this microRNA in the formation of PDAC and other types of human cancer.

Another interesting finding in the present study is the correlation between *BACH1* expression levels and response to gemcitabine chemotherapy and survival time in individuals with PDAC. We found that individuals with the rs372883CC genotype had a stronger response to gemcitabine and longer MST compared with those with the rs372883TT genotype, suggesting that rs372883 genotype has potential to serve as a biomarker for identification or prediction of responsiveness to gemcitabine treatment and prognosis of the disease. These clinical findings can be replicated by in vitro drug sensitivity assays in PDAC cells with overexpression or knockdown of *BACH1* and with different *BACH1* rs372883 genotypes in the presence of *BACH1* expression suppressor miR-1257. The association between *BACH1* genotype and response to gemcitabine and survival time in patients may reflect the function of HO-1 since previous studies have linked HO-1 overexpression to resistance against gemcitabine in pancreatic cancer cells [@B45], [@B46]. Nonetheless, we found that HO-1 can rescue only part of the *BACH1* effect, suggesting that there might be other effectors regulated by *BACH1* involved in gemcitabine sensitivity. Indeed, we also found that the expression levels of *ABCC2*, *MGST1* and *NQO1*, which may be downstream of *BACH1*, also had an effect on gemcitabine sensitivity to some degree. On the other hand, we found that the alteration of EMT- and stemness-associated genes may also play an important role in gemcitabine treatment. A more high-throughput study will be helpful to reveal other potential players. Because of the unavailability of target tissue specimens from most PDAC patients in the clinic, *BACH1* rs372883 genotype would be a good surrogate for prediction if this effect can be further validated in a larger size of sample. However, we failed to find such a predictive effect for the rs372883CT genotype, which might be due to mixed expressing alleles of *BACH1* in this group of the heterozygous genotype.

In conclusion, by a set of functional analyses in this study, we demonstrated that rs372883T\>C change diminishes the interaction of*BACH1* mRNA 3\'UTR with miR-1257, resulting in a high expression of *BACH1* that may more efficiently repress HO-1 expression and consequent oncogenic signaling. These results may explain why rs372883C allele is associated with reduced risk for the development of PDAC as discovered in our previous GWAS in Chinese population. Furthermore, we found that rs372883 genotype is also associated with response to gemcitabine treatment and survival time in patients with PDAC, suggesting that rs372883 genotypes might serve as a biomarker for prediction of gemcitabine treatment efficacy and prognosis of the malignancy.
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![**Expression of *BACH1* in PDAC. (A)** *BACH1*mRNA levels determined by qRT-PCR were significantly lower in PDAC compared with paired adjacent normal tissues (N=75). Results represent mean ± SEM normalized to *GAPDH* and *P*-values are for Student\'s *t-*test. **(B)** *BACH1* protein levels determined by Western blot were significantly lower in PDAC (T) than in paired normal tissues (N). Shown is a representative picture selected from 35 pairs of clinical specimens. **(C)** Representative IHC images (200×) showing *BACH1* protein expression in normal pancreatic tissues (*left*) and PDAC (*right*). Bar scale, 100 μm. **(D-E)** Expression of *BACH1* in published data sets of Pei et al.[@B27] and Badea et al. [@B28] (Oncomine, <https://www.oncomine.org/resource/main.html>). The line in the middle of the box represents the median; bars represent 10th and 90th percentiles and greater values were plotted as individual points. *P*-values are for unpaired Wilcox rank-sum test.](thnov08p3366g001){#F1}

![***BACH1* inhibits PDAC cells proliferation and angiogenesis. (A)** Stable overexpression or knockdown of *BACH1* in CFPAC-1 and BXPC-3 cells. **(B)** Effect of *BACH1* overexpression or knockdown on colony formation of CFPAC-1 and BXPC-3 cells. Results represent colony formation ability relative to Control or shControl set to 100% from three experiments. *P*-values are for Student\'s *t-*test. \*, *P*\<0.05; \*\*, *P*\<0.01 compared with Control or shControl.**(C)** Overexpression of *BACH1* substantially reduced proliferation of both CFPAC-1 and BXPC-3 cells determined by CCK-8 assay. Results are mean ± SEM from three experiments and each experiment had six replicates. \*, *P*\<0.05 compared with control. **(D)** Knockdown of *BACH1* significantly enhanced proliferation of both CFPAC-1 and BXPC-3 cells. Results are mean ± SEM from three experiments and each experiment had six replicates. \*, *P*\<0.05 compared with shControl. **(E-F)** Xenograft tumor formation and growth of CFPAC-1 and BXPC-3 cells with *BACH1* overexpression or knockdown in nude mice. Results are mean ± SEM from 6 animals in each group. \*, *P*\<0.05 compared with Control or shControl. **(G)** Effect of *BACH1* expression on VEGF levels quantified by ELISA in the culture medium of CFPAC-1 or BXPC-3 cells. Results are mean ± SEM from three measurements. \*, *P*\<0.05; \*\*, *P*\<0.01 compared with Control or shControl.**(H)** Effects of culture medium of CFPAC-1 or BXPC-3 cells with *BACH1* overexpression or knockdown on HUVEC tube formation. Results are mean ± SEM from three measurements. \*, *P*\<0.05 compared with Control or shControl.](thnov08p3366g002){#F2}

![***BACH1* negatively regulates HO-1 expression in PDAC cells. (A)** MA plot of the gene expression profile. Eight genes directly regulated by *BACH1* were marked: red, upregulated; blue, downregulated; gray, not significantly changed. The dotted lines indicate the cut-off value of log~2~ fold change (± 0.58).**(B)** *BACH1* binding peaks in the *HMOX1* gene locus based on ChIP-sequencing data (GSM693953 and GSM693952). **(C)** Chromatin immunoprecipitation assays showing binding of *BACH1* to two enhancers EN1 (-9.0kb) and EN2 (-4.0kb) in the upstream of *HMOX1* in CFPAC-1 and BXPC-3 cells. Overexpression of *BACH1* in these cells substantially enhanced enrichment of *BACH1* in EN1 and EN2, while knockdown of *BACH1* substantially decreased the enrichment in these two enhancers. Fold enrichment (mean ± SEM) represents DNA levels associated with *BACH1* or IgG relative to an input control from three independent experiments. IgG served as negative control. \*\*\*, *P*\<0.001 compared with Control or shControl. **(D)** Overexpression of *BACH1* suppressed HO-1 expression while knockdown of *BACH1* elevated HO-1 expression in both mRNA and protein levels in CFPAC-1 and BXPC-3 cells. \*, *P*\<0.05; \*\*\*, *P*\<0.001 compared with Control or shControl. **(E)** *HMOX1* mRNA expression was significantly higher in PDAC compared with their adjacent normal tissues (N=75). Results are mean ± SEM normalized to *GAPDH* and the *P*-values are for Student\'s *t-*test. **(F)** Correlation between *BACH1* and *HMOX1* mRNA levels in PDAC and paired normal tissues (N=75). The RNA levels were determined by qRT-PCR and expressed relative to *GAPDH*. The r- and *P*-values are for Pearson\'s correlation analysis. **(G-H)** Correlation between *BACH1* and *HMOX1* mRNA levels in PDAC and paired normal tissues. Data are from Oncomine database generated by Pei et al. [@B27] and Badea et al. [@B28].](thnov08p3366g003){#F3}

![***BACH1* regulates signaling pathway downstream of HO-1. (A-B)** Western blot analysis of AKT and ERK signaling modules downstream of HO-1 in CFPAC-1 and BXPC-3 cells with overexpression or knockdown of *BACH1*. **(C-E)** A reverse correlation between mRNA levels (N=75) of *BACH1* and mRNA levels of *HIF1A* **(C)** or *VEGF* **(D)** and a positive correlation between mRNA levels of *BACH1* and mRNA levels of *PTEN* **(E)** in normal tissues (*upper panel*) and paired PDAC (*lower panel*). The RNA levels were determined by qRT-PCR relative to *GAPDH*. The r- and *P*-values are for Pearson\'s correlation analysis.](thnov08p3366g004){#F4}

![**Functional relevance of rs372883 variants. (A)** Relative reporter gene activity bearing *BACH1* 3\'UTR fragment with the rs372883T or rs372883C allele in CFPAC-1 and BXPC-3 cells. Results are mean ± SEM from three experiments and each had six replicates. The *P*-values are for Student\'s *t*-test. **(B)** In silico prediction of interaction between miR-1257 and *BACH1* 3\'UTR showing differences in binding within the seed region. **(C)** Relative reporter gene activity of the psiCHECK2-rs372883T and psiCHECK2-rs372883C constructs cotransfected with 1.0, 5.0 and 10.0 pmol of miR-1257 or its inhibitor in CFPAC-1 and BXPC-3 cells. Results are mean ± SEM from three experiments and each had six replicates; *P*-values were for Student\'s *t-*test. **(D-F)** Levels of *BACH1* mRNA, miR-1257 and *HMOX1* mRNA in normal pancreatic tissues adjacent to tumors of subjects with the rs372883 CC (N=11), CT (N=38) or TT (N=26) genotype. Results are mean ± SEM relative to *GAPDH* or *U6*. **(G)** Western blot analysis of AKT and ERK signaling modules downstream of HO-1 in surgically removed PDAC specimens from subjects with the rs372883CC, CT or TT genotype.](thnov08p3366g005){#F5}

![**Gemcitabine sensitivity in PDAC cells depends on *BACH1* in an allele-specific manner. (A)** Effects of *BACH1* on gemcitabine sensitivity in CFPAC-1 and BXPC-3 cells. Results represent mean ± SEM from three independent experiments and each had four replications. \*, *P*\<0.05 and \*\*, *P*\<0.01. **(B-C)** Effect of HO-1 expression on gemcitabine sensitivity in CFPAC-1 and BXPC-3 cells with overexpression **(B)** or knockdown **(C)** of *BACH1*. Results are mean ± SEM from three independent experiments and each had four replications. \*, *P*\<0.05; \*\*, *P*\<0.01 and \*\*\*, *P*\<0.001. **(D-F)** Effect of miR-1257 on gemcitabine sensitivity in BXPC-3 **(D)**, CFPAC-1 **(E)** and Capan-2 **(F)** cells carrying the rs372883 CC, CT or TT genotype, respectively. Cells transiently transfected with miR-1257 or its inhibitor were exposed to gemcitabine at final concentrations ranging from 10^-3^ to 10^3^ nM. Cells were enumerated with the CCK-8 assay at 48h after drug exposure. IC~50~ represents gemcitabine concentration that inhibits cell proliferation by 50%. Results are mean ± SEM from three experiments and each had four replicates. \*, *P*\<0.05 and \*\*\*, *P*\<0.001.](thnov08p3366g006){#F6}

![**Kaplan-Meier estimation of PDAC survival time in 102 patients. (A)** Survival curves by disease stage. **(B)** Survival curves by response to gemcitabine therapy. **(C)** Survival curves by *BACH1* 3\'UTR rs372883 genotypes.](thnov08p3366g007){#F7}

###### 

Response to gemcitabine therapy in patients with PDAC by *BACH1* rs372883 genotypes

  Genotype   Responders\*   Nonresponders\*   OR (95% CI)^§^     *P*
  ---------- -------------- ----------------- ------------------ -------
  TT         4 (25.0)       36 (41.9)         1.00 (Reference)   
  CT         6 (37.5)       40 (46.5)         0.63 (0.15-2.57)   0.514
  CC         6 (37.5)       10 (11.6)         0.15 (0.03-0.68)   0.014

\*Responders include complete response and partial response while nonresponders include stable disease and progressive disease.

^§^OR, odds ratio, was calculated by logistic regression with adjustment for sex, age, tumor stage and surgery.

[^1]: \*These authors contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
